Cincinnati medtech startup Eyas Medical Imaging is leveling up, signing a lease for a new headquarters as it gets ready to roll out its Ascent3T neonatal MRI system to hospitals following recent federal clearance. The move marks a clear shift from lab prototypes to commercial production and comes as the company ramps up its Cincinnati footprint.
On Feb. 5, 2026, the U.S. Food and Drug Administration granted Eyas a 510(k) clearance for the Ascent3T, clearing the device for commercial use in the United States. In a press release, CEO Matt Storer called the clearance a “significant milestone” as the company scales operations and prepares to commercialize later in 2026, according to Business Wire.
The company has now inked a lease for new office space in Cincinnati and plans to roughly double its team as it accelerates manufacturing and sales efforts. Those real-estate and hiring moves are being watched as a concrete signal that Eyas is moving from prototype work to full commercial deployment, according to the Cincinnati Business Courier.
What the Ascent3T Offers
Built around a 3-tesla magnet, the Ascent3T is billed as the first high-field 3T MRI platform designed specifically for neonatal and infant imaging. The system offers whole-body scans and a detachable patient table that allows bedside transfers, along with a virtually helium-free design that can simplify installation inside NICUs, according to AuntMinnie.
New HQ, Jobs and Local Support
Eyas’ website lists an office at 1105 Western Ave. in Cincinnati and highlights partnerships with local organizations, signaling regional backing as the company grows. That expanding footprint and network line up with the kind of municipal and accelerator support early-stage medtech companies often rely on when they move from R&D into production, per Eyas Medical Imaging.
Placing an MRI directly inside the NICU can cut down on risky transports for fragile newborns and help speed diagnosis of brain, heart and lung conditions, which is a key reason hospitals are eyeing dedicated neonatal scanners. The Ascent3T was developed from work at Cincinnati Children’s and was tested on more than 1,700 infant scans during its research phase, a track record that has clinicians and hospital systems closely watching its commercial rollout, according to Cincinnati Children’s.
With the new lease in place and FDA clearance secured, Eyas is positioning itself to sell the Ascent system to hospitals nationwide and scale up operations from Cincinnati later in 2026. Local leaders and investors say keeping startups that can move from prototype to production inside the region is crucial for maintaining high-skilled manufacturing and clinical innovation, per reporting by the Cincinnati Business Courier.
